Cephalon, Inc.

Astrazeneca Ab

E.i. Dupont De Nemours and Company

Dupont Electronics, Inc.

Cephalon France

Teva Sante

Greg A Hostetler

Edward R Bacon

Derek D Dunn

Robert L Hudkins

Thomas R Bailey

Sankar Chatterjee

Nadine C Becknell

Allison L Zulli

Kurt A Josef

Diane E Gingrich

Brigitte Lesur

Babu G Sundar

Christophe Yue

Michael Henry Howard, Jr

Rabindranath Tripathy

Ming Tao

Mohamed A Iqbal

Keith S Learn

Marc Chapdelaine

John McCauley

Philippe Louvet

Jason C Wagner

Lars J S Knutsen

Dominique Schweizer

Marie-Edith Gourdel

Eric Riguet

Nora Sabina Radu

Bruce D Dorsey

Joseph M Salvino

Henry Joseph Breslin

Gregory R Ott

John Donald Summers

George C Morton

Craig A Zificsak

Kerwin D Dobbs

James L Diebold

Glen E Ernst

Karen L Milkiewicz

Eugen F Mesaros

Linda Weinberg

Theodore L Underiner

Gregory J Wells

Joseph Lisko

Jay P Theroff

Tho V Thieu

Denis Yurievich Kondakov

Lucius Kemp

Htay Min Hlaing

Brian C Auman

Bipinchandra Chaudhari

Gerard C Rosse

Chai Kit Ngai

Rachael Hunter

Dannielle Kissel

Robert J McHugh

Mohamed Iqbal

Disclosed is a polyimide having a repeat unit structure of Formula III In Formula III: Rrepresents one or more different tetracarboxylic acid component residues; and Rrepresents one or more different aromatic diamine residues or aromatic diisocyanate residues. 5-100 mol % of Rhas Formula II In Formula II: Ris H, halogen, cyano, hydroxyl, alkyl, heteroalkyl, alkoxy, heteroalkoxy, fluoroalkyl, silyl, hydrocarbon aryl, substituted hydrocarbon aryl, heteroaryl, substituted heteroaryl, ally, or vinyl; Ris halogen, cyano, hydroxyl, alkyl, heteroalkyl, alkoxy, heteroalkoxy, fluoroalkyl, silyl, hydrocarbon aryl, substituted hydrocarbon aryl, heteroaryl, substituted heteroaryl, ally, or vinyl; Rand Rare the same or different and are alkyl, fluoroalkyl, or silyl; x and y are the same or different and are an integer from 0-2; and * indicates a point of attachment.

Polymers for use in electronic devices

There is disclosed a compound which is an N-heterocycle having at least one substituent of Formula 1: wherein: the N-heterocycle is a fused ring N-heterocycle having at least two fused aromatic rings with at least one ring N; Q1, Q2, Q4, and Q5 are the same or different and are selected from the group consisting of N and CR; Q3 is C&#x2014;CN; Ris the same or different at each occurrence and is selected from the group consisting of H, D, CN, hydrocarbon aryl, heteroaryl, deuterated hydrocarbon aryl, and deuterated heteroaryl; and * represents a point of attachment to N in the N-heterocycle; with the proviso that at least one of Q1, Q2, Q4, and Q5 is N.

Electroactive materials

This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.

Tricyclic derivatives and their pharmaceutical use and compositions

The present invention is directed to methods of treating disorders mediated by Histamine Hreceptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine Hreceptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

[object Object]

The present invention provides compounds of formula I: their use as Hantagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.

The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine Hreceptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

Aryl pyridazinone derivatives and their use as H3 receptor ligands

The present invention provides a compound of formula I or a salt form thereof, wherein Q, Q, Q, and Qare as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

Pyrrolotriazines as ALK and JAK2 inhibitors

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R, R, R, R, R, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).

Substituted bicyclic pyrimidines

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R, R, R, R, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.

Thio-substituted biarylmethanesulfinyl derivatives

Substituted pyrazolo[3,4-d]pyrimidines

Thio-substituted biaryl-methanesulfinyl derivatives

Compounds useful for the treatment of pain in accord with the following structural diagram,wherein R, R, R, Rand Rare any of a number of groups as defined in the specification, A and D are as defined in the specification, and pharmaceutical compositions and methods of treatment utilising such compounds.

N-type calcium channel antagonists for the treatment of pain

Growing community of inventors

Newark, DE, United States of America

Greg A Hostetler